$12.4399
0.0999[0.81%]
At close: Apr 25
$12.4399
0[0.00%]
After Hours: 5:37PM EDT
Hims & Hers Health
(NYSE:HIMS)Hims & Hers Health Stock (NYSE:HIMS), Analyst Ratings, Price Targets, Predictions
Hims & Hers Health Inc has a consensus price target of $11.11, established from looking at the 41 latest analyst ratings. The last 3 analyst ratings were released from Jefferies, Canaccord Genuity, and Guggenheim on April 16, 2024, April 10, 2024, and February 27, 2024. With an average price target of $17.33 between Jefferies, Canaccord Genuity, and Guggenheim, there's an implied 39.34% upside for Hims & Hers Health Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Jefferies
Canaccord Genuity
Guggenheim
Citigroup
Piper Sandler
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Hims & Hers Health
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/16/2024 | HIMS | Buy Now | Hims & Hers Health | $12.44 | 20.58% | Jefferies | Glen Santangelo | $17 → $15 | Downgrade | Buy → Hold | Get Alert |
| 04/10/2024 | HIMS | Buy Now | Hims & Hers Health | $12.44 | 60.77% | Canaccord Genuity | Maria Ripps | → $20 | Initiates | → Buy | Get Alert |
| 02/27/2024 | HIMS | Buy Now | Hims & Hers Health | $12.44 | 36.66% | Guggenheim | Jack Wallace | $15 → $17 | Maintains | Buy | Get Alert |
| 02/27/2024 | HIMS | Buy Now | Hims & Hers Health | $12.44 | 28.62% | Citigroup | Daniel Grosslight | $12 → $16 | Maintains | Buy | Get Alert |
| 02/27/2024 | HIMS | Buy Now | Hims & Hers Health | $12.44 | -11.57% | Piper Sandler | Michael Lavery | $9 → $11 | Maintains | Neutral | Get Alert |
| 02/27/2024 | HIMS | Buy Now | Hims & Hers Health | $12.44 | 4.5% | Truist Securities | Jailendra Singh | $10 → $13 | Maintains | Hold | Get Alert |
| 02/26/2024 | HIMS | Buy Now | Hims & Hers Health | $12.44 | -19.61% | Leerink Partners | Michael Cherny | → $10 | Initiates | → Market Perform | Get Alert |
| 01/05/2024 | HIMS | Buy Now | Hims & Hers Health | $12.44 | 20.58% | Tigress Financial | Ivan Feinseth | $14 → $15 | Maintains | Buy | Get Alert |
| 08/09/2023 | HIMS | Buy Now | Hims & Hers Health | $12.44 | -19.61% | Truist Securities | Jailendra Singh | $12 → $10 | Maintains | Hold | Get Alert |
| 08/08/2023 | HIMS | Buy Now | Hims & Hers Health | $12.44 | 12.54% | Credit Suisse | Jonathan Yong | → $14 | Reiterates | Outperform → Outperform | Get Alert |
| 07/28/2023 | HIMS | Buy Now | Hims & Hers Health | $12.44 | -11.57% | TD Cowen | Jonna Kim | → $11 | Initiates | → Outperform | Get Alert |
| 06/15/2023 | HIMS | Buy Now | Hims & Hers Health | $12.44 | 12.54% | Tigress Financial | Ivan Feinseth | $12 → $14 | Reiterates | → Buy | Get Alert |
| 05/30/2023 | HIMS | Buy Now | Hims & Hers Health | $12.44 | -11.57% | Piper Sandler | Michael Lavery | $12 → $11 | Maintains | Neutral | Get Alert |
| 05/09/2023 | HIMS | Buy Now | Hims & Hers Health | $12.44 | 20.58% | B of A Securities | Michael Cherny | $13.5 → $15 | Maintains | Buy | Get Alert |
| 05/09/2023 | HIMS | Buy Now | Hims & Hers Health | $12.44 | -3.54% | Piper Sandler | Michael Lavery | $11 → $12 | Maintains | Neutral | Get Alert |
| 04/27/2023 | HIMS | Buy Now | Hims & Hers Health | $12.44 | 44.7% | Guggenheim | Jack Wallace | $15 → $18 | Maintains | Buy | Get Alert |
| 04/26/2023 | HIMS | Buy Now | Hims & Hers Health | $12.44 | -11.57% | Piper Sandler | Korinne Wolfmeyer | $10 → $11 | Maintains | Neutral | Get Alert |
| 04/11/2023 | HIMS | Buy Now | Hims & Hers Health | $12.44 | -19.61% | Baird | Vikram Kesavabhotla | → $10 | Initiates | → Neutral | Get Alert |
| 03/01/2023 | HIMS | Buy Now | Hims & Hers Health | $12.44 | 12.54% | Credit Suisse | Jonathan Yong | $8 → $14 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Hims & Hers Health (HIMS)?
The latest price target for Hims & Hers Health (NYSE: HIMS) was reported by Jefferies on April 16, 2024. The analyst firm set a price target for $15.00 expecting HIMS to rise to within 12 months (a possible 20.58% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Hims & Hers Health (HIMS)?
The latest analyst rating for Hims & Hers Health (NYSE: HIMS) was provided by Jefferies, and Hims & Hers Health downgraded their hold rating.
When was the last upgrade for Hims & Hers Health (HIMS)?
The last upgrade for Hims & Hers Health Inc happened on February 9, 2023 when Jefferies raised their price target to $11. Jefferies previously had a hold for Hims & Hers Health Inc.
When was the last downgrade for Hims & Hers Health (HIMS)?
The last downgrade for Hims & Hers Health Inc happened on April 16, 2024 when Jefferies changed their price target from $17 to $15 for Hims & Hers Health Inc.
When is the next analyst rating going to be posted or updated for Hims & Hers Health (HIMS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Hims & Hers Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Hims & Hers Health was filed on April 16, 2024 so you should expect the next rating to be made available sometime around April 16, 2025.
Is the Analyst Rating Hims & Hers Health (HIMS) correct?
While ratings are subjective and will change, the latest Hims & Hers Health (HIMS) rating was a downgraded with a price target of $17.00 to $15.00. The current price Hims & Hers Health (HIMS) is trading at is $12.44, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.